Antibody drug-loaded unimicelle conjugates (ADUCs): a novel platform enabling ultra-high DAR
Wednesday, July 16, 2025
2:54 PM – 3:05 PM EDT
Introduction: Current antibody-drug conjugates (ADCs) are limited by low drug-to-antibody ratios (DAR) due to physicochemical instabilities1-2). To overcome this limitation, we engineered a novel platform: antibody-drug-loaded unimicelle (unimer-micelle) conjugates (ADUCs) using single-chain polymer nanoparticles (SCNPs). In this study, we achieved an ultra-high DAR (approximately 40) with favorable properties due to the unimicelle's amphiphilic nature and demonstrated strong antitumor effects in pharmacological studies. We also explored our platform's applicability for fragmented antibodies and affibodies.
Learning Objectives:
At the completion of this activity, participants will know
Understand the design and physicochemical properties of ADUCs, comparing them to traditional ADCs.
Evaluate the antigen-binding specificity, cellular internalization, and antitumor activity of ADUCs.
Explore diverse ADUC applications, including combinations with fragmented antibodies and affibodies.
